QLH12016

QLH12016 is a protein degrader developed by Qilu Pharmaceutical. Its target is Androgen receptor. ClinicalTrials.gov describes the intervention as: An oral androgen receptor PROTAC; QLH12016 will be administered orally at the dose and dosing frequency specified in the protocol. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in prostate cancer. The largest, NCT07198633, plans to enrol 212 participants with primary completion expected 2026-12. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.